Trials / Completed
CompletedNCT04026256
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
Mechanisms Underlying the Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- Female
- Age
- 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to examine, via iliac crest bone biopsies, the mechanism of combined teriparatide and denosumab on the bone of postmenopausal osteoporotic women after 3 months of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teriparatide | teriparatide daily subcutaneous injection |
| DRUG | Denosumab | denosumab subcutaneous injection |
Timeline
- Start date
- 2019-09-02
- Primary completion
- 2022-04-18
- Completion
- 2022-04-18
- First posted
- 2019-07-19
- Last updated
- 2023-08-02
- Results posted
- 2023-08-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04026256. Inclusion in this directory is not an endorsement.